Research shows lysine improves intestinal calcium uptake and reduces urinary calcium loss
STEP 1 showed 14.9% body weight reduction at 2.4 mg weekly SELECT trial : Cardiovascular outcomes study showing 20% MACE reduction in patients with obesity and established CVD without diabetes FLOW trial : Kidney outcomes data demonstrating renal protective effects Oral formulation : Rybelsus provides an oral dosing option at 7-14 mg daily Real-world data : Millions of prescriptions written, providing extensive post-marketing safety surveillance Survodutide Research# Survodutide's evidence base is growing but not yet mature: Phase 2 obesity trial : Demonstrated dose-dependent weight loss up to approximately 19% body weight reduction, exceeding typical GLP-1 monotherapy results Phase 2 MASH data : Histological improvement in liver biopsies, including reduction in hepatic steatosis and inflammation scores Phase 3 programs : Active Phase 3 trials for both obesity and MASH, with results anticipated to define the compound's clinical profile Mechanism validation : Clinical data support the dual mechanism concept, with evidence of both appetite reduction and increased energy expenditure Limitation : No regulatory approvals
They are often blended together in liquid formulations to provide comprehensive cellular support without relying on methylation
And I dont know, we work with a lot of surgeons, we work with a lot of really important people, and say someones not competing, but if something goes wrong, and it comes back that you recommended or you were like, Yeah, try these injectable peptides that are not FDA regulated, and something goes wrong with the surgery or whatever they have, I just dont want that heat
Mikus, D., Grabarevic, Z., Rucman, R., Petek, M., Turkovic, B., Rokotov, D
Animal studies have demonstrated GHK-Cus wound-healing abilities
